Ultragenyx Pharmaceutical Inc (LTS:0LIF)
$ 51.134 0.686 (1.35%) Market Cap: 4.70 Bil Enterprise Value: 3.98 Bil PE Ratio: 0 PB Ratio: 10.88 GF Score: 72/100

Ultragenyx Pharmaceutical Inc GTX-102 Data Update Call Transcript

Oct 26, 2020 / 09:00PM GMT
Release Date Price: $89.12
Operator

Ladies and gentlemen, thank you for standing by. And welcome to Ultragenyx GTX-102 Data Update. (Operator Instructions) I will now hand the conference over to your speaker today, Joshua Higa. You may begin.

Joshua Higa
Ultragenyx Pharmaceutical Inc. - Director of IR & Corporate Communications

Good afternoon. And welcome to the Ultragenyx conference call to discuss preliminary data from the ongoing Phase I/II study of GTX-102 in Angelman Syndrome sponsored by our partner, GeneTx Biotherapeutics. We issued a joint press release earlier detailing the results from the study. Slides covering the study update can be found in our corporate presentation posted in the Investors section of our website at ultragenyx.com.

I am Joshua Higa, Director of Investor Relations. With me today is Emil Kakkis, Chief Executive Officer and President of Ultragenyx; and Scott Stromatt, Chief Medical Officer of our partner company, GeneTx.

I would like to remind investors that this call will include forward-looking statements, including those related to management

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot